The European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance have developed the first set of quality indicators for metastatic breast cancer care to ensure that breast cancer centers meet required standards. A multidisciplinary group of experts identified and defined these indicators, focusing on aspects such as access to care, disease characterization, and treatment protocols. This initiative aims to improve the quality of care for patients with metastatic breast cancer through routine measurement and evaluation.

The research highlights the clinical significance of circulating tumor cell (CTC)-specific microRNA (miRNA) in breast cancer, emphasizing its potential as a noninvasive method for early screening, diagnosis, and monitoring treatment response. CTC detection is linked to patient prognosis, and miRNAs may serve as valuable diagnostic and prognostic biomarkers, although certain challenges must be addressed before their clinical application.

This systematic review analyzes the use of liquid biopsy (LB) for early breast cancer (BC) diagnosis, focusing on biomarkers found in various body fluids, primarily peripheral blood. The findings indicate that LB, particularly through microRNA analysis, demonstrates high sensitivity and specificity for detecting BC, especially in its early stages.

This review highlights the clinical development of therapies targeting ERBB2-low breast cancer, which constitutes about 50% of cases but is currently ineligible for anti-ERBB2 treatments. It discusses the potential of novel therapies like trastuzumab deruxtecan and the need for revised diagnostic criteria to better identify and treat patients with ERBB2-low tumors. Ongoing research may lead to improved strategies for managing this distinct breast cancer subtype.